ReviewCurrent heart failure reports2012
TNF revisited: osteoprotegerin and TNF-related molecules in heart failure.
Review in Current heart failure reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Exploring the Clinical Utility of Osteoprotegerin in Heart Failure-A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2025Pooled it
- Enhancing Inflammatory Factors, Nitric Oxide, and Arterial Stiffness Through Aquatic Walking for Amelioration and Disease Prevention: Targeting in Obese Elderly Women.Mediators of inflammation · 2024Trial
- Beneficial Effects of Baduanjin Exercise on Left Ventricular Remodelling in Patients after Acute Myocardial Infarction: an Exploratory Clinical Trial and Proteomic Analysis.Cardiovascular drugs and therapy · 2021Trial
- Cardiovascular remodeling: key mechanisms and clinical implications linking sarcopenia and heart failure.Frontiers in medicine · 2026Review
- Impaired adenosine pathways in HFpEF: insights into cardiorenal alterations and endothelial responses.Frontiers in pharmacology · 2026Article
- Classification patterns identification of immunogenic cell death-related genes in heart failure based on deep learning.Scientific reports · 2025Article
- Osteoprotegerin Is Essential for the Development of Endothelial Dysfunction Induced by Angiotensin II in Mice.International journal of molecular sciences · 2024Article
- Article
- Heart Failure: Is There an Ideal Biomarker?Reviews in cardiovascular medicine · 2023Review
- Phytochemicals in the treatment of inflammation-associated diseases: the journey from preclinical trials to clinical practice.Frontiers in pharmacology · 2023Review
- Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases.Heart failure reviews · 2022Review
- The relevance of microRNA in post-infarction left ventricular remodelling and heart failure.Heart failure reviews · 2019Review
- Association of OPG-RANKL ratio with left ventricular hypertrophy and geometric remodeling in male overweight/obese youths.Journal of endocrinological investigation · 2019Article
- Myocardial apoptosis and mesenchymal stem cells with acute exercise.Physiological reports · 2017Article
- From bones to blood pressure, developing novel biologic approaches targeting the osteoprotegein pathway for pulmonary vascular disease.Pharmacology & therapeutics · 2017Review
- Amlodipine and atorvastatin improved hypertensive cardiac hypertrophy through regulation of receptor activator of nuclear factor kappa B ligand/receptor activator of nuclear factor kappa B/osteoprotegerin system in spontaneous hypertension rats.Experimental biology and medicine (Maywood, N.J.) · 2016Article
- Sleep-disordered breathing is associated with depletion of circulating endothelial progenitor cells and elevation in pulmonary arterial pressure in patients with decompensated systolic heart failure.Journal of geriatric cardiology : JGC · 2015Article
- Obesity-related inflammation & cardiovascular disease: efficacy of a yoga-based lifestyle intervention.The Indian journal of medical research · 2014Review
- The NO/ONOO-cycle as the central cause of heart failure.International journal of molecular sciences · 2013Review
- The physiology of cardiovascular disease and innovative liposomal platforms for therapy.International journal of nanomedicine · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pathophysiological role of tumor necrosis factor (TNF) in myocardial failure has been extensively examined in experimental and clinical studies. Recent studies suggest that other members of the TNF/TNF receptor superfamily (TNFSF/TNFRSF) also may play a pathogenic role in chronic HF. TNF ligands, and in particular members of the TNFRSF, are expressed by a wide variety of cells, including myocardial cells. By activating the nuclear factor-κB (NF-κB) and death-related pathways, TNF ligands can induce a variety of effects within the myocardium, including apoptosis, hypertrophy, inflammation, and extracellular matrix remodeling. Among several TNFSF members that have been shown activated in HF, the OPG/RANK/RANKL (osteoprotegerin/receptor activator of NF-κB/RANK ligand) axis may be of importance in the pathogenesis of this disorder through different mechanisms. In this paper, we revisited the role of TNFSF/TNFRSF in the pathophysiology of HF, possibly representing new targets for therapy as well as new biomarkers in this disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.